NASDAQ: SLGLSol Gel Technologies Ltd Stock
$0.95+0.09 (+10.47%)
Updated Apr 16, 2024
SLGL Price
$0.95
Fair Value Price
$0.06
Market Cap
$26.35M
52 Week Low
$0.79
52 Week High
$4.20
P/E
-0.94x
P/B
0.68x
P/S
19.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.55M
Earnings
-$27.24M
Gross Margin
100%
Operating Margin
-1,752.77%
Profit Margin
-1,752.8%
Debt to Equity
0.17
Operating Cash Flow
-$18M
Beta
0.54
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SLGL Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLGL ($0.95) is overvalued by 1,608.86% relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLGL ($0.95) is not significantly undervalued (1,608.86%) relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLGL due diligence checks available for Premium users.
Be the first to know about important SLGL news, forecast changes, insider trades & much more!
SLGL News
Valuation
SLGL fair value
Fair Value of SLGL stock based on Discounted Cash Flow (DCF)
Price
$0.95
Fair Value
$0.06
Overvalued by
1,616.09%
SLGL ($0.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLGL ($0.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
15.24x
Market
41.98x
SLGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
5.83x
SLGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLGL's financial health
Profit margin
Revenue
$447.0k
Net Income
-$4.8M
Profit Margin
-1,081.9%
SLGL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SLGL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$45.3M
Liabilities
$6.6M
Debt to equity
0.17
SLGL's short-term assets ($41.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLGL's short-term assets ($41.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SLGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLGL vs Biotech Stocks
Sol Gel Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.